Drug Discovery Outsourcing Market Worth $4.4 Billion by 2025: Grand View Research, Inc.
SAN FRANCISCO, August 9, 2018 /PRNewswire/ --
The global drug discovery outsourcing market size is expected to reach USD 4.44 billion by 2025 at an 8.14% CAGR, according to a new report by Grand View Research, Inc. Urging need to identify potential drug candidates for various chronic diseases is anticipated to fuel growth.
Technological advances in in silico drug designing and accelerating integration of Artificial Intelligence (AI) in drug discovery are driving industry progress. Multiple applications of AI algorithms in drug design and discovery provide opportunities for players to offer specialized drug discovery services. It is useful for processes such as target and compound selection, predictive analytics, screening, and drug repurposing.
Projected rise in adoption of outsourcing over the forecast period is expected to boost market revenue generation. Half of the drug discovery processes are anticipated to be outsourced, thereby creating massive opportunities for CROs, CMOs, and CDMOs to expand their market presence.
Number of collaborations among these organizations, key pharmaceutical players, and several universities has increased over the past few years. This rise in alliance further supports the projected increase in growth potential.
High cost and high risk of drug failure are major challenges faced in drug discovery. However, advances in technology that increase efficiency of drug discovery, coupled with increased adoption of highly advanced technology to provide specialized services, allow outsourcing companies to overcome these challenges.
Escalating incidence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) is projected to indirectly propel market growth. Advancements in technologies, such as emergence of Artificial Intelligence (AI) in the pharmaceutical industry, is also anticipated to accelerate industry progress
Moreover, increasing incidences of antibiotic resistance as well as drug resistance have improved focus on discovery of novel compounds to treat conditions such as Multidrug-Resistant TB (MDR-TB)
Based on workflow, lead identification and candidate optimization is slated for impressive growth owing to high bottlenecks in this workflow segment
By therapeutic area, oncology drug discovery outsourcing is fueled by increasing demand for oncology solutions, coupled with expanding government support in cancer research
North America dominates the global market owing to high focus on R&D in identification of novel drug candidates, along with presence of key players
Asia Pacific is projected to witness the fastest growth over the forecast period as a result of increasing number of CRO, CMOs, and CDMOs in emerging countries. Rising trend of outsourcing manufacturing and R&D activities to countries such as China and India will aid growth in the region
Some of the major players are Charles River; EVOTEC, Laboratory Corporation of America Holdings; GenScript, Merck & Co., Inc.; Jubilant Biosys; Thermo Fisher Scientific, Inc.; Oncodesign; Albany Molecular Research, Inc.; WuXi AppTec; Dalton Pharma Services; Pharmaceutical Product Development, LLC; DiscoverX Corporation; and QIAGEN
Collaboration of players with key pharmaceutical companies and academics and research centers is observed to increase in recent years.
Browse related reports by Grand View Research:
Antibiotics Market - The antibiotics market was valued at USD 39.8 billion in 2015 and is expected to witness a CAGR of 4.0% over the forecast period.
Biodefense Market - The global biodefense market size was over USD 9.5 billion in 2015. The market is expected to witness growth owing to technological advancements in pathogen detection techniques in the forensic division.
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market - The global Human Immunodeficiency Virus (HIV)-1 therapeutics market was valued at USD 13.5 billion in the year 2015 and is estimated to grow at a CAGR of 1.4% from 2016 to 2025.
Pulmonary Arterial Hypertension (PAH) Market - The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 owing to the increasing prevalence and incidence rates of this disease.
Grand View Research has segmented the global drug discovery outsourcing market on the basis of workflow, therapeutic area, drug type, and region:
Drug Discovery Outsourcing Workflow Outlook(Revenue, USD Million, 2013 - 2025)
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Other Associated Workflow
Drug Discovery Outsourcing Therapeutic Area Outlook (Revenue, USD Million, 2013 - 2025)
Respiratory System
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
Cardiovascular
Endocrine
Gastrointestinal
Immunomodulation
Anti-Infective
Central Nervous System
Dermatology
Genitourinary System
Drug Discovery Outsourcing Drug Type Outlook (Revenue, USD Million, 2013 - 2025)
Small Molecules
Large Molecules (Biopharmaceuticals)
Drug Discovery Outsourcing Regional Outlook (Revenue, USD Million, 2013 - 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Middle East and Africa (MEA)
South Africa
Explore the BI enabled intuitive market research database,The Grand Library, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit:
All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...
The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the United States, announced the overwhelming success of its 2024 "Are You O-K+" campaign, which marked May 1 (5.1) as...
The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and...
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...